REVEAL HPS-3 TIMI-55, 2017 trial summary    PDF trial summary

A randomised clinical trial investigating the effect of anacetrapib versus placebo in high risk patients already taking statins

        Z

NCT01252953    



Studied treatment anacetrapib 100mg daily
Control treatment placebo



Patients high risk patients already taking statins
Size30624



Blindness double-blind Inclusion period
Follow-up duration median 4 years Centers
Lost to FU geographical localisation
Primary endpoint coronary events Design Parallel groups



EndpointX1N1X0N0TE95% CI Carotid revascularization - 30000 - 0 no data cardiovascular events - 30624 - 0 no data Cardiovascular death, myocardial infarction, stroke - 30000 - 0 no data Cardiovascular death - 30000 - 0 no data all cause death - 30000 - 0 no data Nonfatal myocardial infarction - 30000 - 0 no data coronary events - 30000 - 0 no data Nonfatal stroke - 30000 - 0 no data stroke - 30000 - 0 no data Coronary revascularization - 30000 - 0 no data CHD death - 30000 - 0 no data0,22,01,0

Merck announced on june 26, 2017 that the REVEAL trial with anacetrapib had met its primary endpoint, significantly reducing the rate of coronary death, MI, and coronary revascularization



Registering number NCT01252953 (see trial on clinicaltrials.gov)
Code Name

Comment: Full results of REVEAL will be presented on August 29 at the European Society of Cardiology meeting in Barcelona, Spain